Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Buy
52
VNRX Quote, Financials, Valuation and Earnings
Last price:
$0.57
Seasonality move
:
-5.39%
Day range:
$0.55 - $0.58
52-week range:
$0.40 - $0.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
38.65x
P/B ratio:
--
Volume:
251.5K
Avg. volume:
248.2K
1-year change:
-24%
Market cap:
$57.8M
Revenue:
$1.2M
EPS (TTM):
-$0.27
Analysts' Opinion
-
Consensus RatingVolitionRX has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.93, VolitionRX has an estimated upside of 422.11% from its current price of $0.56.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $0.56.
Fair Value
-
According to the consensus of 3 analysts, VolitionRX has 422.11% upside to fair value with a price target of $2.93 per share.
VNRX vs. S&P 500
-
Over the past 5 trading days, VolitionRX has overperformed the S&P 500 by 2.35% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
VolitionRX does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
VolitionRX has grown year-over-year revenues for 1 quarter straight. In the most recent quarter VolitionRX reported revenues of $246.4K.
Earnings Growth
-
VolitionRX has grown year-over-year earnings for 0 quarters straight. In the most recent quarter VolitionRX reported earnings per share of -$0.06.
Enterprise value:
60.3M
EV / Invested capital:
-2.67x
Price / LTM sales:
38.65x
EV / EBIT:
--
EV / Revenue:
46.10x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.70x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-190.36%
Net Income Margin (TTM):
-1836.21%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-2191.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $342K | $797K | $1.3M | $171.5K | $246.4K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$31.8M | -$35.3M | -$23.9M | -$8.4M | -$5.4M | |
| EBITDA | -$30.3M | -$33.6M | -$22.6M | -$8.1M | -$5.1M | |
| Diluted EPS | -$0.56 | -$0.46 | -$0.27 | -$0.10 | -$0.06 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $34.7M | $26M | $12M | $13.5M | $3.3M | |
| Total Assets | $40.5M | $31.7M | $18M | $19.4M | $8.5M | |
| Current Liabilities | $6M | $17.5M | $17.2M | $31.5M | $8.3M | |
| Total Liabilities | $9.3M | $20.9M | $21M | $36.1M | $37.5M | |
| Total Equity | $31.2M | $10.8M | -$3M | -$16.6M | -$29M | |
| Total Debt | $3.2M | $3.4M | $3.7M | $4.5M | $6.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$27.6M | -$17.7M | -$21.8M | -$8.3M | -$4.3M | |
| Cash From Investing | -$1.6M | -$962K | -$496.9K | -$78.8K | -$1.8K | |
| Cash From Financing | $15.3M | $20.6M | $12.5M | -$209.4K | $3.7M | |
| Free Cash Flow | -$29.3M | -$18.6M | -$22.3M | -$8.4M | -$4.3M | |
VNRX
Sector
Market Cap
$57.8M
$34.2M
Price % of 52-Week High
62.31%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
-19.63%
-0.6%
1-Year Price Total Return
-16.3%
-35.99%
Beta (5-Year)
1.072
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.56
200-day SMA
Sell
Level
$0.60
Bollinger Bands (100)
Buy
Level
0.5 - 0.6
Chaikin Money Flow
Sell
Level
-25.5M
20-day SMA
Buy
Level
$0.51
Relative Strength Index (RSI14)
Buy
Level
60.99
ADX Line
Buy
Level
20.52
Williams %R
Neutral
Level
-36.4444
50-day SMA
Buy
Level
$0.50
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
11.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-43.0106)
Sell
CA Score
(Annual)
Level (-13.2542)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (27.9595)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Stock Forecast FAQ
In the current month, VNRX has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The VNRX average analyst price target in the past 3 months is $2.93.
-
Where Will VolitionRX Stock Be In 1 Year?
According to analysts, the consensus estimate is that VolitionRX share price will rise to $2.93 per share over the next 12 months.
-
What Do Analysts Say About VolitionRX?
Analysts are divided on their view about VolitionRX share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that VolitionRX is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is VolitionRX's Price Target?
The price target for VolitionRX over the next 1-year time period is forecast to be $2.93 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is VNRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for VolitionRX is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VNRX?
You can purchase shares of VolitionRX via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase VolitionRX shares.
-
What Is The VolitionRX Share Price Today?
VolitionRX was last trading at $0.57 per share. This represents the most recent stock quote for VolitionRX. Yesterday, VolitionRX closed at $0.56 per share.
-
How To Buy VolitionRX Stock Online?
In order to purchase VolitionRX stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is up 29.48% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is up 20.55% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 17.78% over the past day.
